Markets
← Back to Stocks
JNJ
JOHNSON + JOHNSON
Health Care · Pharmaceuticals
$237.56
+0.16%
Vol: 0.2M
Araverus Market Read
Thursday, March 19, 2026
ICOTYDE FDA approval and analyst price target increases power overnight momentum as psoriasis blockbuster gains traction
Johnson & Johnson declined $0.60 (-0.25%) in pre-market to $243.79 and fell $0.39 (-0.16%) after-hours to $242.80, showing minimal overnight weakness. The company received FDA approval for ICOTYDE, the first IL-23 receptor oral peptide for moderate-to-severe plaque psoriasis, with analysts highlighting blockbuster potential. HSBC and UBS both raised price targets to $280, supporting the stock's positioning as investors seek healthcare exposure amid macroeconomic uncertainty.
Price 50d 200d
Previous Market Reads
2 of 2 daysSector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$572.6B
P/E (TTM)21.5
Forward P/E18.9
Beta0.33
Div Yield219.00%
Prev Close$237.19
RSI (14-Day)
27Oversold
0305070100
52-Week Range
$141.50$237.56$251.71
From High-5.6%
From Low+67.9%
Moving Averages
50d SMA
$232.81+2.0%
200d SMA
$192.25+23.6%
Price above both MAs — bullish structure.
Returns
1W
-1.9%
1M
-2.5%
3M
+14.1%
6M
+35.6%
1Y
+48.7%
YTD
+15.2%
Volume
Today206K
20d Avg8.0M
Ratio0.03x